Immunomodulating effects of the new anti-rheumatic drug tenidap on collagen-induced arthritis.
We investigated the in vivo action of the newly developed anti-rheumatic agent tenidap, CP-66,248 (Pfizer Inc., New York), on arthritis in collagen-induced arthritic mice. The inhibitory effect of tenidap on the development of arthritis was statistically more significant than piroxicam. The serum anti-type II collagen antibody titer was markedly inhibited in the mice treated by tenidap. These results suggest that, unlike NSAIDs, tenidap inhibits the progress of collagen-induced arthritis through its immunomodulating effect.
Matsushita
I
I
Department of Orthopaedics and Rheumatology, Toyama Medical and Pharmaceutical University, Japan.
Matsuno
H
H
Kadowaki
K M
KM
Okada
C
C
Tsuji
H
H
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D000917:Antibody Formation; D001169:Arthritis, Experimental / Q000188:drug therapy / Q000276:immunology* / Q000503:physiopathology; D001175:Arthrography; D001323:Autoantibodies / Q000097:blood / Q000187:drug effects* / Q000276:immunology*; D003094:Collagen / Q000276:immunology; D005121:Extremities / Q000000981:diagnostic imaging; D005260:Female; D007211:Indoles / Q000737:chemistry / Q000494:pharmacology*; D051379:Mice; D008811:Mice, Inbred DBA; D000078183:Oxindoles; D010894:Piroxicam / Q000494:pharmacology
D000894:Anti-Inflammatory Agents, Non-Steroidal; D001323:Autoantibodies; D007211:Indoles; D000078183:Oxindoles; D010894:Piroxicam; D003094:Collagen; C062866:tenidap